Current pharmacotherapy of overactive bladder

• Type: Article in International Scientific Journal
• Date: 2021

Authors

Kreydin, EI (Author) Other; Gomes, CM (Author) Other; Francisco Cruz (Author) FMUP

Journal

Title: International Braz J Urol

Vol. 47

Pages: 1091-1107

ISSN: 1677-5538

Indexing

ISI Web of Knowledge - 14 Citations

Scopus - 17 Citations

Other information

Authenticus ID: P-00V-FXA

DOI: 10.1590/s1677-5538.ibju.2021.99.12

Abstract (EN): Overactive bladder is a symptom complex consisting of bothersome storage urinary symptoms that is highly prevalent among both sexes and has a significant impact on quality of life. Various antimuscarinic agents and the beta-3 agonists mirabegron and vibegron are currently available for the treatment of OAB. Each drug has specific pharmacologic properties, dosing schedule and tolerability profile, making it essential to individualize the medical treatment for the patient's characteristics and expectations. In this manuscript, we review the most important factors involved in the contemporary pharmacological treatment of OAB.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 17